Current status of GV1001 and other telomerase vaccination strategies in the treatment of cancer

V E Shaw, D J Naisbitt, E Costello, W Greenhalf, B K Park, J P Neoptolemos, G W Middleton

Research output: Contribution to journalArticlepeer-review

32 Citations (Scopus)

Abstract

GV1001 is a telomerase-specific, promiscuous class II peptide vaccine which is currently in an advanced stage of clinical development. This article reviews the biological rationale underpinning the design of ongoing studies with the vaccine as well as its immunogenicity and clinical activity. It places GV1001 in the context of other immunotherapeutic approaches targeting telomerase and assesses the chances of the vaccine becoming a future standard of care in the treatment of cancer.

Original languageEnglish
Pages (from-to)1007-16
Number of pages10
JournalExpert Review of Vaccines
Volume9
Issue number9
DOIs
Publication statusPublished - Sep 2010

Keywords

  • Cancer Vaccines
  • Humans
  • Immunotherapy
  • Neoplasms
  • Peptide Fragments
  • Telomerase
  • Vaccination

Fingerprint

Dive into the research topics of 'Current status of GV1001 and other telomerase vaccination strategies in the treatment of cancer'. Together they form a unique fingerprint.

Cite this